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Editorial
Cyclin Dl, another molecule of the year?
One of the aims of carcinogenesis research is to identify
the precise molecular alterations responsible for neo-
plastic transformation. Normal cell cycle control is dis-
rupted in malignant cells which are unable to regulate
their proliferation correctly. Understanding how the
cell cycle control operates therefore represents a fun-
damental problem in cancer biology. Work in recent
years has led to the conclusion that cyclins, and cyctin-
dependent kinases (CDKs) together with their inhibi-
tors constitute a complicated network of positive and
negative regulation circuits. These basic regulatory
mechanisms are common to all mammalian cells and
act at specific time points during the cell cycle (Figure
During the Gl phase, D-type cyclins appear to act as
growth factor sensors, driving cells through the first
restriction point (START in yeast), beyond which cells
are committed to divide. Cyclin Dl together with spe-
cific kinases (CDK4, CDK6) and one particular kinase
inhibitor (pl6) appears to play a central role in the
regulation of the proliferation status. Activated CDK4,
through phosphorylation and complex formation with
cyclin Dl, inactivates the retinoblastoma protein (pRb).
This results in the release from pRb of a transcription
factor, E2F, which then activates many genes necessary
for cell division. The pl6 protein suppresses this
process by competitively binding to the CDK4 mol-
ecule (Figure 2). Component genes of this specific con-
trol pathway are frequently compromised in malignant
cells (for review see [1-5]).
The apparently ever-growing list of cell cycle regula-
tors makes it increasingly difficult to keep abreast of
this rapidly developing field, let alone for oncologists to
think of clinical applications of these basic discoveries.
However, some aspects are becoming clearer with
respect to cancer, one of the most important proteins is
cyclin Dl. It is now well established that cyclin Dl has
oncogenic functions: constitutive overexpression in
rodent cells can shorten the Gl phase [6], and similarly,
in breast cancer cells arrested in Gl, cyclin Dl induc-
tion is sufficient to complete the cell cycle and to
shorten the Gl-S phase [7]. Transfection of the cyclin
Dl gene constructs into normal fibroblasts stimulates
proliferation by reduction of the Gl-S phase [6], and
when transfected into normal fibroblasts with activated
H-ras, it promotes the formation of fibrosarcomas in
nude mice [8]. Moreover, mice carrying an active cyclin
Dl transgene develop mammary hyperplasia and
adenocarcinoma [9]. When overexpression of cyclin Dl
is targeted to the lymphoid system, the transgenic mice
develop lymphomas in the presence of c-myc over-
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Figure I. Combinatorial interactions of cyclins and cyclin depend-
ent kinases (CDK) during the cell cycle.
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Figure 2. Model for Gl restriction-point control by cyclin Dl:
Growth factors induce the transcription of the cyclin Dl gene
(CCND1) and positively regulate its assembly with CDK4 (and
CDK6, not shown). The cyclin D1-CDK4 complex is activated by
cyclin-activating kinase (CAK - cyclin H + CDK7) and the func-
tional holoenzyme then phosphorylates the retinoblastoma protein,
releasing and thus activating the E2F transcription factor. The
CDKN2 gene (encoding pl6) inactivates CDK4 and induces accel-
erated turnover of unbound cyclin Dl during the S phase.
expression [10, 11]. Very recently, cyclin Dl over-
expression has been found at early stages of tumour
development, in particular, in carcinoma in situ of the
breast [12] and in bronchial epithelia of resection mar-
gins of non-small-cell lung cancer that were micro-
scopically tumour-free [13].
The region of chromosome I lq l3 encoding the
cyclin Dl gene (CCND1) is frequently altered at the
cytogenetic level in malignant disease. Increased gene
copy numbers (gene amplification) have been found in
breast, ovarian, bladder, esophageal, gallbladder, stom-
ach, laryngeal, lung and liver cancers [1]. In esophageal
[14], laryngeal [15] and head and neck tumours [16],
CCND1 amplification correlates with poor prognosis, a
high incidence of distant metastasis and frequent recur-
rences. In almost all cases, amplification of the I lq l3
region was associated with overexpression of cyclin Dl.
In lymphoproliferative disorders, another mechanism
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may also lead to cyclin Dl overexpression: Transloca-
tion between the bcl-1 region, upstream of CCND1,
and the immunoglobulin (Ig) heavy chain locus on
chromosome 14 [17, 18] results in elevated transcrip-
tion of CCND1, with high levels of cyclin Dl [19-22].
The translocation t(ll;14Xql3;q32) occurs in 90% of
mantle cell lymphomas and splenic lymphomas with
villous lymphocytes as well as in a small percentage of
certain aggressive lymphocytic and plasma cell leukae-
mias [19-21,23-25].
This issue of Annals of Oncology carries an interest-
ing paper expanding our knowledge of cyclin Dl in
hairy cell leukaemia (HCL). De Boer et al. [26] report
on cyclin Dl overexpression in the majority of patients
with HCL using both molecular and genetic methods.
These findings are in full agreement with the very
recently published study by Bosch et al. [27]. Thirty-
eight of 40 HCL patients in the two studies showed
cyclin Dl overexpression. The level of expression is
significantly lower than in mantle cell lymphomas;
nevertheless, this finding is very interesting and rather
unexpected, given the lack of evidence for molecular
lesions involving CCND1 in HCL.
Except for some lymphoproliferative disorders with
the bcl-1 rearrangement, lymphoid tissues such as ton-
sils, spleen and lymph nodes apparently have no or
very low levels of cyclin Dl expression [19, 28]. De
Boer et al. [26] and Bosch et al. [27] were unable to
explain the mechanism of cyclin Dl overexpression
and CCND1 deregulation in HCL. Neither structural
anomalies within I lq l3 (cytogenetic and molecular
techniques) nor gene amplification were detected. Al-
though rearrangements cannot be excluded outside the
regions examined, translocation appears not to be a
main mechanism responsible for cyclin Dl overexpres-
sion in HCL. Although the B-cell lineage of HCL is
well established [29], there are several lines of evidence
indicating some phenotypic and functional similarities
between hairy cells and cells of monocyte/macrophage
lineage [30], which normally express cyclin Dl [31].
Thus, it remains to be seen whether this cyclin Dl over-
expression is at least partially responsible for the malig-
nant behaviour of the hairy cells, or whether, as specu-
lated by the authors, it might constitute a physiological
characteristic shared by hairy cells. Additionally, it may
represent an unspecific upregulation occurring as a
result of the deregulated cycle network. Further work is
therefore needed to establish the role of cyclin Dl in
HCL.
For instance, the examination of allele specific
CCND1 expression in HCL would point to a possible
role in malignancy. Were allelic imbalance observed in
PCR-amplified cDNA it might be concluded that only
one parental allele was responsible for cyclin Dl over-
expression. This would lead to the assumption that
there had been an alteration, such as a mutation within
a CCND1 control region or splice site (RNA proces-
sing). This phenomenon was recently demonstrated
[32, 33]: Using immunostaining in a series of non-
small-cell lung tumours, cyclin Dl was overexpressed
in almost 30% of cases with no apparent structural ab-
normalities of CCND1, as assessed by Southern blot-
ting and PCR. In these tumours we detected imbal-
ances in allele-specific expression by RT-PCR and
restriction fragment length polymorphism analysis of a
HaeIR polymorphism. Thus, genetic alteration of
CCND1 appears to be a key abnormality in lung car-
cinogenesis. Such a result in HCL would strengthen the
evidence of a direct role for cyclin Dl in the disease.
Deregulation or loss of function of genes involved in
the control of progression through the Gl restriction
point (CCND1, CDK4, CDKN2, RBI) is common in
human cancers. Conversely, lesions within the many
other genes controlling aspects of the cell cycle (cyclin
A, B, E, CDKs or CDK inhibitor genes) is much less
frequent. In particular, overexpression of cyclin Dl has
now been observed in around 50% of the most com-
mon and least treatable malignancies, including colo-
rectal, head and neck, esophageal, breast, uterus and
lung carcinomas, melanomas and sarcomas [14,16, 32,
34-37]. In addition, various studies have demonstrated
that blocking the action of cyclin Dl in vitro, with anti-
bodies or antisense RNA prevents the growth of many
tumour cell lines [6,38]. However, evidence from mice
in which both parental cyclin Dl genes have been
knocked out suggests that complete loss of cyclin Dl
function might have only limited effects on overall
viability or normal cell proliferation in the adult [39].
These findings raise the exciting possibility that thera-
peutic agents directed against elements of this pathway,
in particular cyclin Dl, might prove not only successful
in the treatment of common malignancies but also have
relatively few side effects. Further research is needed to
show whether such an approach might be transferred
from the laboratory bench to patients. Should this turn
out to be successful, then, without doubt, another edi-
torial entitled 'Cyclin Dl, the molecule of the century1
will have to be written!
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